Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture

D Gabel, D Preusse, D Haritz, F Grochulla, K Haselsberger, H Fankhauser, Crister Ceberg, H D Peters, U Klotz

Research output: Contribution to journalArticlepeer-review

Abstract

The disposition of Na2B12H11SH (BSH) in patients with malignant glioma has been investigated, in preparation for a Phase I clinical trial of boron neutron capture therapy. BSH was found to possess a linear disposition over the dosage interval investigated (up to 75 mg/kg). A bi-phasic blood pharmacokinetics was observed. Tumour-to-blood ratios showed variations between patients between 0.08 and 5.1. The data allow the definition of amount of BSH and timing of infusion for a Phase I clinical trial protocol.
Original languageEnglish
Pages (from-to)606-612
JournalActa Neurochirurgica
Volume139
Issue number7
DOIs
Publication statusPublished - 1997

Subject classification (UKÄ)

  • Radiology, Nuclear Medicine and Medical Imaging

Free keywords

  • Boron neutron capture therapy
  • glioma
  • BSH

Fingerprint

Dive into the research topics of 'Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture'. Together they form a unique fingerprint.

Cite this